These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 21332734)

  • 1. A review of the clinical implications of bisphosphonates in dentistry.
    Borromeo GL; Tsao CE; Darby IB; Ebeling PR
    Aust Dent J; 2011 Mar; 56(1):2-9. PubMed ID: 21332734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.
    Kunchur R; Need A; Hughes T; Goss A
    J Oral Maxillofac Surg; 2009 Jun; 67(6):1167-73. PubMed ID: 19446200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates and osteonecrosis of the jaws: science and rationale.
    Gutta R; Louis PJ
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Aug; 104(2):186-93. PubMed ID: 17448709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates and bisphosphonate induced osteonecrosis.
    Sawatari Y; Marx RE
    Oral Maxillofac Surg Clin North Am; 2007 Nov; 19(4):487-98, v-vi. PubMed ID: 18088900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
    King AE; Umland EM
    Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates and osteonecrosis of the jaws.
    Mariotti A
    J Dent Educ; 2008 Aug; 72(8):919-29. PubMed ID: 18676801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of bisphosphonate-induced osteonecrosis of the jaw.
    Schilling J
    Northwest Dent; 2008; 87(3):34-5, 37-8, 40. PubMed ID: 18663869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: a prospective clinical study.
    Lee CY; Suzuki JB
    Implant Dent; 2010 Feb; 19(1):29-38. PubMed ID: 20147814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CTX and its role in managing patients exposed to oral bisphosphonates.
    Dodson TB
    J Oral Maxillofac Surg; 2010 Feb; 68(2):487-8; author reply 488-9. PubMed ID: 20116729
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety profile of intravenous bisphosphonates.
    Mehrotra B
    Semin Oncol; 2007 Dec; 34(6 Suppl 4):S24-7. PubMed ID: 18068487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.
    Khan AA; Sándor GK; Dore E; Morrison AD; Alsahli M; Amin F; Peters E; Hanley DA; Chaudry SR; Dempster DW; Glorieux FH; Neville AJ; Talwar RM; Clokie CM; Al Mardini M; Paul T; Khosla S; Josse RG; Sutherland S; Lam DK; Carmichael RP; Blanas N; Kendler D; Petak S; St-Marie LG; Brown J; Evans AW; Rios L; Compston JE;
    J Rheumatol; 2008 Jul; 35(7):1391-7. PubMed ID: 18528958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.
    ; Khosla S; Burr D; Cauley J; Dempster DW; Ebeling PR; Felsenberg D; Gagel RF; Gilsanz V; Guise T; Koka S; McCauley LK; McGowan J; McKee MD; Mohla S; Pendrys DG; Raisz LG; Ruggiero SL; Shafer DM; Shum L; Silverman SL; Van Poznak CH; Watts N; Woo SB; Shane E
    J Oral Maxillofac Surg; 2008 Jun; 66(6):1320-1; author reply 1321-2. PubMed ID: 18486811
    [No Abstract]   [Full Text] [Related]  

  • 14. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part I: biological concepts with a review of the literature.
    Lee CY; Suzuki JB
    Implant Dent; 2009 Dec; 18(6):492-500. PubMed ID: 20009603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Osteonecrosis of the jaw and bisphophonates in oncology].
    Facon T; Bensadoun RJ; Blanc JL; Confavreux C; Gourmet R; Maes JM; Penel G; Vieillard MH; Woeller A
    Bull Cancer; 2008 Apr; 95(4):413-8. PubMed ID: 18495570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonate-related osteonecrosis of the jaw.
    Feller L; Wood NH; Khammissa RA; Chikte UM; Bouckaert M; Lemmer J
    SADJ; 2011 Feb; 66(1):30-2. PubMed ID: 21510174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteonecrosis in the jaws of patients who are using oral biphosphonates to treat osteoporosis.
    Dello Russo NM; Jeffcoat MK; Marx RE; Fugazzotto P
    Int J Oral Maxillofac Implants; 2007; 22(1):146-53. PubMed ID: 17340909
    [No Abstract]   [Full Text] [Related]  

  • 18. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.
    Marx RE; Cillo JE; Ulloa JJ
    J Oral Maxillofac Surg; 2007 Dec; 65(12):2397-410. PubMed ID: 18022461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates and the dental patient: Part 2.
    Zak M; Spina AM; Spinazze RP; Perkinson WL; Spinazze DJ
    Compend Contin Educ Dent; 2007 Sep; 28(9):510-5; quiz 516, 528. PubMed ID: 17907374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteonecrosis of the jaw and bisphosphonates--putting the risk in perspective.
    Bolland M; Hay D; Grey A; Reid I; Cundy T
    N Z Med J; 2006 Dec; 119(1246):U2339. PubMed ID: 17151713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.